文献速递临床试验与 GCP

立体定向体部放疗追加治疗孤立性局部胰腺癌复发的全国随机对照试验(ARCADE)

A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE).
PubMed 文献 · Trials · 2022-10-28

ARCADE试验采用「队列内试验」设计嵌套于荷兰胰腺癌前瞻性队列(PACAP),纳入原发灶切除后孤立性局部胰腺导管腺癌(PDAC)复发患者,随机接受标准治疗联合5次8 Gy立体定向体部放疗(SBRT)或单纯标准治疗,共174例,主要终点为复发后生存,次要终点为生活质量。

要点

  • ARCADE为嵌套于PACAP前瞻性队列的全国随机对照试验,计划纳入174例孤立性局部PDAC复发患者。
  • 干预为在标准治疗基础上追加5次8 Gy的SBRT,对照为单纯标准治疗。
  • 主要终点为复发后生存,最重要的次要终点为生活质量。

核心结论

  • 研究假设:与单纯标准治疗相比,追加SBRT可改善PDAC切除后孤立性局部复发患者的生存和生活质量。

研究设计与样本

  • ARCADE为嵌套于荷兰胰腺癌前瞻性队列(PACAP)的「队列内试验」设计的全国随机对照试验。
  • 纳入PACAP中原发灶切除后孤立性局部PDAC复发、且已知情同意参与未来随机研究的患者,共计划纳入174例。
  • 患者随机接受标准治疗联合局部治疗(5次8 Gy SBRT)或单纯标准治疗。

关键数值与推荐

  • 主要研究终点为复发后生存。
  • 最重要的次要终点为生活质量。
  • 试验注册号ClinicalTrials.gov NCT04881487,注册日期2021年5月11日。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Disease recurrence is the main cause of mortality after resection of pancreatic ductal adenocarcinoma (PDAC). In 20-30% of resected patients, isolated local PDAC recurrence occurs. Retrospective studies have suggested that stereotactic body radiation therapy (SBRT) might lead to improved local control in these patients, potentially having a beneficial effect on both survival and quality of life. The "nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy" (ARCADE) will investigate the value of SBRT in addition to standard of care in patients with isolated local PDAC recurrence compared to standard of care alone, regarding both survival and quality of life outcomes. METHODS: The ARCADE trial is nested within a prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the 'Trials within Cohorts' design. All PACAP participants with isolated local PDAC recurrence after primary resection who provided informed consent for being randomized in future studies are eligible. Patients will be randomized for local therapy (5 fractions of 8 Gy SBRT) in addition to standard of care or standard of care alone. In total, 174 patients will be included. The main study endpoint is survival after recurrence. The most important secondary endpoint is quality of life. DISCUSSION: It is hypothesized that additional SBRT, compared to standard of care alone, improves survival and quality of life in patients with isolated local recurrence after PDAC resection. TRIAL REGISTRATION: ClinicalTrials.gov registration NCT04881487 . Registered on May 11, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. van Goor IWJM, Daamen LA, Besselink MG, et al. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE). Trials. 2022. PMID: 36307892. doi:10.1186/s13063-022-06829-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。